1.
Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, et al. Test
sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
Neurobiol Aging. 2012 Oct;33(10):2272-81.
2.
Whitehead D, Tunnard C, Hurt C, Wahlund LO, Mecocci P, Tsolaki M, et al.
Frontotemporal atrophy associated with paranoid delusions in women with Alzheimer's
disease. Int Psychogeriatr. 2012 Jan;24(1):99-107.
3.
Vedin I, Cederholm T, Freund-Levi Y, Basun H, Garlind A, Irving GF, et al.
Effects of DHA- Rich n-3 Fatty Acid Supplementation on Gene Expression in Blood
Mononuclear Leukocytes: The OmegAD Study. PLoS One. 2012;7(4):e35425.
4.
van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, et al.
Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
Neurology. 2012 Sep 26.
5.
Spulber G, Niskanen E, Macdonald S, Kivipelto M, Padilla D, Julkunen V, et
al. Evolution of global and local grey matter atrophy on serial MRI scans during the
progression from MCI to AD. Curr Alzheimer Res. 2012 Feb 1.
6.
Schmidt R, Berghold A, Jokinen H, Gouw AA, van der Flier WM, Barkhof F,
et al. White matter lesion progression in LADIS: frequency, clinical effects, and sample
size calculations. Stroke. 2012 Oct;43(10):2643-7.
7.
Qiu C, Zhang Y, Bronge L, Herlitz A, Aspelin P, Backman L, et al. Medial
temporal lobe is vulnerable to vascular risk factors in men: a population-based study.
Eur J Neurol. 2012 Jan 17.
8.
Poggesi A, Gouw A, van der Flier W, Pracucci G, Chabriat H, Erkinjuntti T,
et al. Cerebral white matter changes are associated with abnormalities on neurological
examination in non-disabled elderly: the LADIS study. J Neurol. 2012 Nov 20.
9.
Miralbell J, Spulber G, Hooshmand B, Besga A, Mataro M, CedazoMinguez A, et al. Grey Matter and Cognitive Patterns in Cognitive Impaired Subjects
Using CSF Biomarker Cut-Offs. J Alzheimers Dis. 2012 Feb 13.
10.
Miralbell J, Soriano JJ, Spulber G, Lopez-Cancio E, Arenillas JF, Bargallo
N, et al. Structural brain changes and cognition in relation to markers of vascular
dysfunction. Neurobiol Aging. 2012 May;33(5):1003 e9- e17.
11.
Lovden M, Laukka EJ, Rieckmann A, Kalpouzos G, Li TQ, Jonsson T, et al.
The dimensionality of between-person differences in white matter microstructure in old
age. Hum Brain Mapp. 2012 Feb 14.
12.
Looi JC, Walterfang M, Velakoulis D, Macfarlane MD, Svensson LA,
Wahlund LO. Frontotemporal dementia as a frontostriatal disorder: Neostriatal
morphology as a biomarker and structural basis for an endophenotype. Aust N Z J
Psychiatry. 2012 May;46(5):422-34.
13.
Liu Y, Julkunen V, Paajanen T, Westman E, Wahlund LO, Aitken A, et al.
Education increases reserve against Alzheimer's disease-evidence from structural MRI
analysis. Neuroradiology. 2012 Jan 14.
14.
Lindberg O, Westman E, Karlsson S, Ostberg P, Svensson LA, Simmons A,
et al. Is the subcallosal medial prefrontal cortex a common site of atrophy in Alzheimer's
disease and frontotemporal lobar degeneration? Front Aging Neurosci. 2012;4:32.
15.
Lindberg O, Walterfang M, Looi JC, Malykhin N, Ostberg P, Zandbelt B, et
al. Hippocampal Shape Analysis in Alzheimer's Disease and Frontotemporal Lobar
Degeneration Subtypes. J Alzheimers Dis. 2012 Mar 13.
16.
Lindberg O, Manzouri A, Westman E, Wahlund LO. A comparison between
volumetric data generated by voxel-based morphometry and manual parcellation of
multimodal regions of the frontal lobe. AJNR Am J Neuroradiol. 2012 Nov;33(10):195763.
17.
Jacobs HI, Visser PJ, Van Boxtel MP, Frisoni GB, Tsolaki M, Papapostolou
P, et al. Association between white matter hyperintensities and executive decline in mild
cognitive impairment is network dependent. Neurobiol Aging. 2012 Jan;33(1):201 e1-8.
18.
Howner K, Eskildsen SF, Fischer H, Dierks T, Wahlund LO, Jonsson T, et
al. Thinner cortex in the frontal lobes in mentally disordered offenders. Psychiatry Res.
2012 Aug;203(2-3):126-31.
19.
Grieder M, Crinelli RM, Koenig T, Wahlund LO, Dierks T, Wirth M.
Electrophysiological and behavioral correlates of stable automatic semantic retrieval in
aging. Neuropsychologia. 2012 Jan;50(1):160-71.
20.
Greco I, Day N, Riddoch-Contreras J, Reed J, Soininen H, Kloszewska I, et
al. Alzheimer's disease biomarker discovery using in silico literature mining and clinical
validation. J Transl Med. 2012;10:217.
21.
Gothe F, Enache D, Wahlund LO, Winblad B, Crisby M, Lokk J, et al.
Cerebrovascular diseases and depression: epidemiology, mechanisms and treatment.
Panminerva Med. 2012 Sep;54(3):161-70.
22.
Frederiksen KS, Garde E, Skimminge A, Barkhof F, Scheltens P, van
Straaten EC, et al. Corpus Callosum Tissue Loss and Development of Motor and Global
Cognitive Impairment: The LADIS Study. Dement Geriatr Cogn Disord. 2012 Jan
19;32(4):279-86.
23.
Firbank MJ, Teodorczuk A, van der Flier WM, Gouw AA, Wallin A,
Erkinjuntti T, et al. Relationship between progression of brain white matter changes and
late-life depression: 3-year results from the LADIS study. Br J Psychiatry. 2012
Jul;201:40-5.
24.
Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB, et al. EFNS
task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol. 2012
Aug 20.
25.
Eriksdotter-Jonhagen M, Linderoth B, Lind G, Aladellie L, Almkvist O,
Andreasen N, et al. Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal
Forebrain in Patients with Alzheimer's Disease. Dement Geriatr Cogn Disord. 2012 Feb
22;33(1):18-28.
26.
Damangir S, Manzouri A, Oppedal K, Carlsson S, Firbank MJ, Sonnesyn H,
et al. Multispectral MRI segmentation of age related white matter changes using a
cascade of support vector machines. J Neurol Sci. 2012 Aug 23.
27.
Cavallin L, Loken K, Engedal K, Oksengard AR, Wahlund LO, Bronge L, et
al. Overtime reliability of medial temporal lobe atrophy rating in a clinical setting. Acta
Radiol. 2012 Apr 1;53(3):318-23.
28.
Cavallin L, Bronge L, Zhang Y, Oksengard AR, Wahlund LO, Fratiglioni L,
et al. Comparison between visual assessment of MTA and hippocampal volumes in an
elderly, non-demented population. Acta Radiol. 2012 Jun 1;53(5):573-9.
29.
Besga A, Cedazo-Minguez A, Kareholt I, Solomon A, Bjorkhem I, Winblad
B, et al. Differences in brain cholesterol metabolism and insulin in two subgroups of
patients with different CSF biomarkers but similar white matter lesions suggest different
pathogenic mechanisms. Neurosci Lett. 2012 Feb 29;510(2):121-6.
30.
Westman E, Wahlund LO, Foy C, Poppe M, Cooper A, Murphy D, et al.
Magnetic resonance imaging and magnetic resonance spectroscopy for detection of
early Alzheimer's disease. J Alzheimers Dis. 2011;26 Suppl 3:307-19.
31.
Westman E, Simmons A, Zhang Y, Muehlboeck JS, Tunnard C, Liu Y, et al.
Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and
healthy controls. Neuroimage. 2011 Jan 15;54(2):1178-87.
32.
Westman E, Simmons A, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M,
et al. AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated
MRI classification accuracy in Europe and North America. Neuroimage. 2011 Oct
1;58(3):818-28.
33.
Westman E, Cavallin L, Muehlboeck JS, Zhang Y, Mecocci P, Vellas B, et
al. Sensitivity and specificity of medial temporal lobe visual ratings and multivariate
regional MRI classification in Alzheimer's disease. PLoS One. 2011;6(7):e22506.
34.
Tunnard C, Whitehead D, Hurt C, Wahlund LO, Mecocci P, Tsolaki M, et al.
Apathy and cortical atrophy in Alzheimer's disease. Int J Geriatr Psychiatry. 2011
Jul;26(7):741-8.
35.
Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, et
al. Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease. PLoS One.
2011;6(12):e28527.
36.
Sundberg M, Christiansson A, Lindahl C, Wahlund L, Birgersson C.
Cleaning effectiveness of chlorine-free detergents for use on dairy farms. J Dairy Res.
2011 Feb;78(1):105-10.
37.
Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, et
al. The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's
disease: experience from the first 24 months. Int J Geriatr Psychiatry. 2011
Jan;26(1):75-82.
38.
Ryberg C, Rostrup E, Paulson OB, Barkhof F, Scheltens P, van Straaten
EC, et al. Corpus callosum atrophy as a predictor of age-related cognitive and motor
impairment: a 3-year follow-up of the LADIS study cohort. J Neurol Sci. 2011 Aug
15;307(1-2):100-5.
39.
Norberg J, Graff C, Almkvist O, Ewers M, Frisoni GB, Frolich L, et al.
Regional differences in effects of APOE epsilon4 on cognitive impairment in nondemented subjects. Dement Geriatr Cogn Disord. 2011;32(2):135-42.
40.
Miralbell J, Soriano JJ, Spulber G, Lopez-Cancio E, Arenillas JF, Bargallo
N, et al. Structural brain changes and cognition in relation to markers of vascular
dysfunction. Neurobiol Aging. 2011 Oct 18.
41.
Looi JC, Walterfang M, Styner M, Niethammer M, Svensson LA, Lindberg
O, et al. Shape analysis of the neostriatum in subtypes of frontotemporal lobar
degeneration: neuroanatomically significant regional morphologic change. Psychiatry
Res. 2011 Feb 28;191(2):98-111.
42.
Liu Y, Paajanen T, Zhang Y, Westman E, Wahlund LO, Simmons A, et al.
Combination analysis of neuropsychological tests and structural MRI measures in
differentiating AD, MCI and control groups--the AddNeuroMed study. Neurobiol Aging.
2011 Jul;32(7):1198-206.
43.
Li TQ, Wahlund LO. The search for neuroimaging biomarkers of
Alzheimer's disease with advanced MRI techniques. Acta Radiol. 2011 Mar 1;52(2):21122.
44.
Furney SJ, Simmons A, Breen G, Pedroso I, Lunnon K, Proitsi P, et al.
Genome-wide association with MRI atrophy measures as a quantitative trait locus for
Alzheimer's disease. Mol Psychiatry. 2011 Nov;16(11):1130-8.
45.
Furney SJ, Kronenberg D, Simmons A, Guntert A, Dobson RJ, Proitsi P, et
al. Combinatorial markers of mild cognitive impairment conversion to Alzheimer's
disease--cytokines and MRI measures together predict disease progression. J
Alzheimers Dis. 2011;26 Suppl 3:395-405.
46.
Costafreda SG, Dinov ID, Tu Z, Shi Y, Liu CY, Kloszewska I, et al.
Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive
impairment. Neuroimage. 2011 May 1;56(1):212-9.
47.
Westman E, Wahlund LO, Foy C, Poppe M, Cooper A, Murphy D, et al.
Combining MRI and MRS to distinguish between Alzheimer's disease and healthy
controls. J Alzheimers Dis. 2010;22(1):171-81.
48.
Vedin I, Cederholm T, Freund-Levi Y, Basun H, Hjorth E, Irving GF, et al.
Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral
supplementation of omega3 fatty acids: the OmegAD study. J Lipid Res. 2010
May;51(5):1179-85.
49.
Wahlund LO. [Increased number of multimorbidity patients put demands on
health care]. Lakartidningen. 2010 Nov 3-9;107(44):2702.
50.
Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et
al. Association of plasma clusterin concentration with severity, pathology, and
progression in Alzheimer disease. Arch Gen Psychiatry. 2010 Jul;67(7):739-48.
51.
Teodorczuk A, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, Wallin A, et
al. Relationship between baseline white-matter changes and development of late-life
depressive symptoms: 3-year results from the LADIS study. Psychol Med. 2010
Apr;40(4):603-10.
52.
Spulber G, Niskanen E, MacDonald S, Smilovici O, Chen K, Reiman EM, et
al. Whole brain atrophy rate predicts progression from MCI to Alzheimer's disease.
Neurobiol Aging. 2010 Sep;31(9):1601-5.
53.
Schmidt R, Ropele S, Ferro J, Madureira S, Verdelho A, Petrovic K, et al.
Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly
study. Stroke. 2010 May;41(5):e402-8.
54.
Oksengard AR, Cavallin L, Axelsson R, Andersson C, Nagga K, Winblad B,
et al. Lack of accuracy for the proposed 'dubois criteria' in Alzheimer's disease: a
validation study from the Swedish brain power initiative. Dement Geriatr Cogn Disord.
2010;30(4):374-80.
55.
Looi JC, Walterfang M, Styner M, Svensson L, Lindberg O, Ostberg P, et al.
Shape analysis of the neostriatum in frontotemporal lobar degeneration, Alzheimer's
disease, and controls. Neuroimage. 2010 Jul 1;51(3):970-86.
56.
Liu Y, Paajanen T, Zhang Y, Westman E, Wahlund LO, Simmons A, et al.
Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild
cognitive impairment to Alzheimer's disease. Neurobiol Aging. 2010 Aug;31(8):1375-85.
57.
Liu Y, Paajanen T, Westman E, Zhang Y, Wahlund LO, Simmons A, et al.
APOE epsilon2 allele is associated with larger regional cortical thicknesses and
volumes. Dement Geriatr Cogn Disord. 2010;30(3):229-37.
58.
Liu Y, Paajanen T, Westman E, Wahlund LO, Simmons A, Tunnard C, et al.
Effect of APOE epsilon4 allele on cortical thicknesses and volumes: the AddNeuroMed
study. J Alzheimers Dis. 2010;21(3):947-66.
59.
Jacobs HI, Visser PJ, Van Boxtel MP, Frisoni GB, Tsolaki M, Papapostolou
P, et al. The association between white matter hyperintensities and executive decline in
mild cognitive impairment is network dependent. Neurobiol Aging. 2010 Aug 23.
60.
Furney SJ, Simmons A, Breen G, Pedroso I, Lunnon K, Proitsi P, et al.
Genome-wide association with MRI atrophy measures as a quantitative trait locus for
Alzheimer's disease. Mol Psychiatry. 2010 Nov 30.
61.
Famer D, Wahlund LO, Crisby M. Rosuvastatin reduces microglia in the
brain of wild type and ApoE knockout mice on a high cholesterol diet; Implications for
prevention of stroke and AD. Biochem Biophys Res Commun. 2010 Oct 12.
62.
Crisby M, Bronge L, Wahlund LO. Low levels of high density lipoprotein
increase the severity of cerebral white matter changes: implications for prevention and
treatment of cerebrovascular diseases. Curr Alzheimer Res. 2010 Sep 1;7(6):534-9.
63.
Babiloni C, Visser PJ, Frisoni G, De Deyn PP, Bresciani L, Jelic V, et al.
Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective
memory complaint. Neurobiol Aging. 2010 Oct;31(10):1787-98.
64.
Zhang Y, Londos E, Minthon L, Wattmo C, Blennow K, Liu HJ, et al. Medial
temporal lobe atrophy increases the specificity of cerebrospinal fluid biomarkers in
Alzheimer disease with minor cerebrovascular changes. Acta Radiol. 2009
Jul;50(6):674-81.
65.
Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et
al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology
in patients with subjective cognitive impairment or mild cognitive impairment in the
DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009 Jul;8(7):619-27.
66.
Westman E, Spenger C, Oberg J, Reyer H, Pahnke J, Wahlund LO. In vivo
1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice
after donepezil treatment. BMC Neurosci. 2009;10:33.
67.
van de Pol LA, Verhey F, Frisoni GB, Tsolaki M, Papapostolou P, Nobili F,
et al. White matter hyperintensities and medial temporal lobe atrophy in clinical
subtypes of mild cognitive impairment: the DESCRIPA study. J Neurol Neurosurg
Psychiatry. 2009 Oct;80(10):1069-74.
68.
Wahlund K, Fischer H, Dierks T, Wahlund LO, Wiberg MK, Jonsson T, et al.
[Psychopathy and brain imaging--a literature review. With focus on functional magnetic
resonance tomography]. Lakartidningen. 2009 Feb 4-10;106(6):361-5.
69.
Solomon A, Leoni V, Kivipelto M, Besga A, Oksengard AR, Julin P, et al.
Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without
objective cognitive impairment but not in those with Alzheimer's disease. Neurosci Lett.
2009 Oct 2;462(1):89-93.
70.
Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, et
al. MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad
Sci. 2009 Oct;1180:47-55.
71.
Ropele S, Seewann A, Gouw AA, van der Flier WM, Schmidt R, Pantoni L,
et al. Quantitation of brain tissue changes associated with white matter hyperintensities
by diffusion-weighted and magnetization transfer imaging: the LADIS (Leukoaraiosis
and Disability in the Elderly) study. J Magn Reson Imaging. 2009 Feb;29(2):268-74.
72.
Ostberg P, Bogdanovic N, Wahlund LO. Articulatory agility in cognitive
decline. Folia Phoniatr Logop. 2009;61(5):269-74.
73.
Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, Soininen H,
et al. AddNeuroMed--the European collaboration for the discovery of novel biomarkers
for Alzheimer's disease. Ann N Y Acad Sci. 2009 Oct;1180:36-46.
74.
Looi JC, Svensson L, Lindberg O, Zandbelt BB, Ostberg P, Orndahl E, et
al. Putaminal volume in frontotemporal lobar degeneration and Alzheimer disease:
differential volumes in dementia subtypes and controls. AJNR Am J Neuroradiol. 2009
Sep;30(8):1552-60.
75.
Looi JC, Maller JJ, Pagani M, Hogberg G, Lindberg O, Liberg B, et al.
Caudate volumes in public transportation workers exposed to trauma in the Stockholm
train system. Psychiatry Res. 2009 Feb 28;171(2):138-43.
76.
Lindberg O, Ostberg P, Zandbelt BB, Oberg J, Zhang Y, Andersen C, et al.
Cortical morphometric subclassification of frontotemporal lobar degeneration. AJNR Am
J Neuroradiol. 2009 Jun;30(6):1233-9.
77.
Irving GF, Freund-Levi Y, Eriksdotter-Jonhagen M, Basun H, Brismar K,
Hjorth E, et al. Omega-3 fatty acid supplementation effects on weight and appetite in
patients with Alzheimer's disease: the omega-3 Alzheimer's disease study. J Am Geriatr
Soc. 2009 Jan;57(1):11-7.
78.
Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, et al.
Changes in white matter as determinant of global functional decline in older
independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability)
study cohort. BMJ. 2009;339:b2477.
79.
Freund-Levi Y, Hjorth E, Lindberg C, Cederholm T, Faxen-Irving G, Vedin I,
et al. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and
plasma in Alzheimer's disease: the OmegAD study. Dement Geriatr Cogn Disord.
2009;27(5):481-90.
80.
Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, et
al. Validation of Alzheimer's disease CSF and plasma biological markers: the
multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging
Initiative (E-ADNI). Exp Gerontol. 2009 Sep;44(9):579-85.
81.
Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT,
et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in
subjects with elevated levels of tau in cerebrospinal fluid and the APOE
epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord. 2009;27(5):458-64.
82.
Blahak C, Baezner H, Pantoni L, Poggesi A, Chabriat H, Erkinjuntti T, et al.
Deep frontal and periventricular age related white matter changes but not basal ganglia
and infratentorial hyperintensities are associated with falls: cross sectional results from
the LADIS study. J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):608-13.
83.
Zhang Y, Londos E, Minthon L, Wattmo C, Liu H, Aspelin P, et al.
Usefulness of computed tomography linear measurements in diagnosing Alzheimer's
disease. Acta Radiol. 2008 Feb;49(1):91-7.
84.
Volpe U, Federspiel A, Mucci A, Dierks T, Frank A, Wahlund LO, et al.
Cerebral connectivity and psychotic personality traits. A diffusion tensor imaging study.
Eur Arch Psychiatry Clin Neurosci. 2008 Aug;258(5):292-9.
85.
Visser PJ, Verhey FR, Boada M, Bullock R, De Deyn PP, Frisoni GB, et al.
Development of screening guidelines and clinical criteria for predementia Alzheimer's
disease. The DESCRIPA Study. Neuroepidemiology. 2008;30(4):254-65.
86.
Vedin I, Cederholm T, Freund Levi Y, Basun H, Garlind A, Faxen Irving G,
et al. Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine
release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr. 2008
Jun;87(6):1616-22.
87.
Vannini P, Lehmann C, Dierks T, Jann K, Viitanen M, Wahlund LO, et al.
Failure to modulate neural response to increased task demand in mild Alzheimer's
disease: fMRI study of visuospatial processing. Neurobiol Dis. 2008 Sep;31(3):287-97.
88.
Wallin A, Eriksson S, Kilander L, Wahlund LO, Astrand R, Nilsson C.
[Cognitive medicine--field of knowledge for future specialist education]. Lakartidningen.
2008 Jun 25-Jul 1;105(26-27):1956-7.
89.
Sihlbom C, Davidsson P, Sjogren M, Wahlund LO, Nilsson CL. Structural
and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease
patients and healthy individuals. Neurochem Res. 2008 Jul;33(7):1332-40.
90.
Ryberg C, Rostrup E, Sjostrand K, Paulson OB, Barkhof F, Scheltens P, et
al. White matter changes contribute to corpus callosum atrophy in the elderly: the
LADIS study. AJNR Am J Neuroradiol. 2008 Sep;29(8):1498-504.
91.
Ostberg P, Fernaeus SE, Bogdanovic N, Wahlund LO. Word sequence
production in cognitive decline: forward ever, backward never. Logoped Phoniatr Vocol.
2008;33(3):126-35.
92.
Oberg J, Spenger C, Wang FH, Andersson A, Westman E, Skoglund P, et
al. Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice.
Neurobiol Aging. 2008 Sep;29(9):1423-33.
93.
Miranda B, Madureira S, Verdelho A, Ferro J, Pantoni L, Salvadori E, et al.
Self-perceived memory impairment and cognitive performance in an elderly
independent population with age-related white matter changes. J Neurol Neurosurg
Psychiatry. 2008 Aug;79(8):869-73.
94.
Looi JC, Lindberg O, Zandbelt BB, Ostberg P, Andersen C, Botes L, et al.
Caudate nucleus volumes in frontotemporal lobar degeneration: differential atrophy in
subtypes. AJNR Am J Neuroradiol. 2008 Sep;29(8):1537-43.
95.
Looi JC, Lindberg O, Liberg B, Tatham V, Kumar R, Maller J, et al.
Volumetrics of the caudate nucleus: reliability and validity of a new manual tracing
protocol. Psychiatry Res. 2008 Aug 30;163(3):279-88.
96.
Hagnelius NO, Wahlund LO, Nilsson TK. CSF/serum folate gradient:
physiology and determinants with special reference to dementia. Dement Geriatr Cogn
Disord. 2008;25(6):516-23.
97.
Gouw AA, van der Flier WM, van Straaten EC, Pantoni L, Bastos-Leite AJ,
Inzitari D, et al. Reliability and sensitivity of visual scales versus volumetry for evaluating
white matter hyperintensity progression. Cerebrovasc Dis. 2008;25(3):247-53.
98.
Gouw AA, van der Flier WM, Pantoni L, Inzitari D, Erkinjuntti T, Wahlund
LO, et al. On the etiology of incident brain lacunes: longitudinal observations from the
LADIS study. Stroke. 2008 Nov;39(11):3083-5.
99.
Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pantoni L,
Poggesi A, et al. Progression of white matter hyperintensities and incidence of new
lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke. 2008
May;39(5):1414-20.
100.
Frisoni GB, Henneman WJ, Weiner MW, Scheltens P, Vellas B, Reynish E,
et al. The pilot European Alzheimer's Disease Neuroimaging Initiative of the European
Alzheimer's Disease Consortium. Alzheimers Dement. 2008 Jul;4(4):255-64.
101.
Freund-Levi Y, Basun H, Cederholm T, Faxen-Irving G, Garlind A, Grut M,
et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on
neuropsychiatric symptoms. Int J Geriatr Psychiatry. 2008 Feb;23(2):161-9.
102.
Fernaeus SE, Ostberg P, Hellstrom A, Wahlund LO. Cut the coda: early
fluency intervals predict diagnoses. Cortex. 2008 Feb;44(2):161-9.
103.
Dyrby TB, Rostrup E, Baare WF, van Straaten EC, Barkhof F, Vrenken H,
et al. Segmentation of age-related white matter changes in a clinical multi-center study.
Neuroimage. 2008 Jun;41(2):335-45.
104.
Cavallin L, Axelsson R, Wahlund LO, Oksengard AR, Svensson L, Juhlin P,
et al. Voxel-based correlation between coregistered single-photon emission computed
tomography and dynamic susceptibility contrast magnetic resonance imaging in
subjects with suspected Alzheimer disease. Acta Radiol. 2008 Dec;49(10):1154-61.
105.
Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Naslund J, Axelman K,
et al. Clinical and neuropathological features of the arctic APP gene mutation causing
early-onset Alzheimer disease. Arch Neurol. 2008 Apr;65(4):499-505.
106.
Baezner H, Blahak C, Poggesi A, Pantoni L, Inzitari D, Chabriat H, et al.
Association of gait and balance disorders with age-related white matter changes: the
LADIS study. Neurology. 2008 Mar 18;70(12):935-42.
107.
Westman E, Spenger C, Wahlund LO, Lavebratt C. Carbamazepine
treatment recovered low N-acetylaspartate+N-acetylaspartylglutamate (tNAA) levels in
the megencephaly mouse BALB/cByJ-Kv1.1(mceph/mceph). Neurobiol Dis. 2007
Apr;26(1):221-8.
108.
Verdelho A, Madureira S, Ferro JM, Basile AM, Chabriat H, Erkinjuntti T, et
al. Differential impact of cerebral white matter changes, diabetes, hypertension and
stroke on cognitive performance among non-disabled elderly. The LADIS study. J
Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1325-30.
109.
Vannini P, Almkvist O, Dierks T, Lehmann C, Wahlund LO. Reduced
neuronal efficacy in progressive mild cognitive impairment: a prospective fMRI study on
visuospatial processing. Psychiatry Res. 2007 Oct 15;156(1):43-57.
110.
Wahlund LO. Neuroimaging should not be a routine investigation in all
cases of suspected dementia. Int Psychogeriatr. 2007 Jun;19(3):526-33.
111.
Teodorczuk A, O'Brien JT, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T,
et al. White matter changes and late-life depressive symptoms: longitudinal study. Br J
Psychiatry. 2007 Sep;191:212-7.
112.
Ryberg C, Rostrup E, Stegmann MB, Barkhof F, Scheltens P, van Straaten
EC, et al. Clinical significance of corpus callosum atrophy in a mixed elderly population.
Neurobiol Aging. 2007 Jun;28(6):955-63.
113.
Pettersson AF, Olsson E, Wahlund LO. Effect of divided attention on gait in
subjects with and without cognitive impairment. J Geriatr Psychiatry Neurol. 2007
Mar;20(1):58-62.
114.
Ostberg P, Crinelli RM, Danielsson R, Wahlund LO, Bogdanovic N,
Fernaeus SE. A temporal lobe factor in verb fluency. Cortex. 2007 Jul;43(5):607-15.
115.
Lehmann C, Koenig T, Jelic V, Prichep L, John RE, Wahlund LO, et al.
Application and comparison of classification algorithms for recognition of Alzheimer's
disease in electrical brain activity (EEG). J Neurosci Methods. 2007 Apr 15;161(2):34250.
116.
Korf ES, van Straaten EC, de Leeuw FE, van der Flier WM, Barkhof F,
Pantoni L, et al. Diabetes mellitus, hypertension and medial temporal lobe atrophy: the
LADIS study. Diabet Med. 2007 Feb;24(2):166-71.
117.
Jelic V, Wahlund LO. Diagnostic imaging devices in Alzheimer's disease.
Expert Rev Med Devices. 2007 Jul;4(4):475-87.
118.
Inzitari D, Simoni M, Pracucci G, Poggesi A, Basile AM, Chabriat H, et al.
Risk of rapid global functional decline in elderly patients with severe cerebral agerelated white matter changes: the LADIS study. Arch Intern Med. 2007 Jan 8;167(1):818.
119.
Giedraitis V, Sundelof J, Irizarry MC, Garevik N, Hyman BT, Wahlund LO,
et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted
in Alzheimer's disease. Neurosci Lett. 2007 Nov 12;427(3):127-31.
120.
Bronge L, Wahlund LO. White matter changes in dementia: does radiology
matter? Br J Radiol. 2007 Dec;80 Spec No 2:S115-20.
121.
Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I,
et al. Neurochemical aftermath of amateur boxing. Arch Neurol. 2006 Sep;63(9):127780.
122.
van Straaten EC, Fazekas F, Rostrup E, Scheltens P, Schmidt R, Pantoni
L, et al. Impact of white matter hyperintensities scoring method on correlations with
clinical data: the LADIS study. Stroke. 2006 Mar;37(3):836-40.
123.
Wahlund LO. [Life-long mental exercise can prevent Alzheimer disease].
Lakartidningen. 2006 Mar 22-28;103(12):912-3.
124.
Pantoni L, Poggesi A, Basile AM, Pracucci G, Barkhof F, Chabriat H, et al.
Leukoaraiosis predicts hidden global functioning impairment in nondisabled older
people: the LADIS (Leukoaraiosis and Disability in the Elderly) Study. J Am Geriatr Soc.
2006 Jul;54(7):1095-101.
125.
O'Brien JT, Firbank MJ, Krishnan MS, van Straaten EC, van der Flier WM,
Petrovic K, et al. White matter hyperintensities rather than lacunar infarcts are
associated with depressive symptoms in older people: the LADIS study. Am J Geriatr
Psychiatry. 2006 Oct;14(10):834-41.
126.
Marcusson J, Hoffman W, Klingen S, Minthon L, Sandman PO, Stromqvist
J, et al. [There is a need to reform dementia care. Resources are not used optimally-time for evidence-based care]. Lakartidningen. 2006 Mar 29-Apr 4;103(13):1022-4, 7-8.
127.
Madureira S, Verdelho A, Ferro J, Basile AM, Chabriat H, Erkinjuntti T, et
al. Development of a neuropsychological battery for the Leukoaraiosis and Disability in
the Elderly Study (LADIS): experience and baseline data. Neuroepidemiology.
2006;27(2):101-16.
128.
Leoni V, Shafaati M, Salomon A, Kivipelto M, Bjorkhem I, Wahlund LO. Are
the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive
impairment? Neurosci Lett. 2006 Apr 10-17;397(1-2):83-7.
129.
Lehmann C, Vannini P, Wahlund LO, Almkvist O, Dierks T. Increased
sensitivity in mapping task demand in visuospatial processing using reaction-timedependent hemodynamic response predictors in rapid event-related fMRI. Neuroimage.
2006 Jun;31(2):505-12.
130.
Krishnan MS, O'Brien JT, Firbank MJ, Pantoni L, Carlucci G, Erkinjuntti T,
et al. Relationship between periventricular and deep white matter lesions and
depressive symptoms in older people. The LADIS Study. Int J Geriatr Psychiatry. 2006
Oct;21(10):983-9.
131.
Gouw AA, Van der Flier WM, van Straaten EC, Barkhof F, Ferro JM,
Baezner H, et al. Simple versus complex assessment of white matter hyperintensities in
relation to physical performance and cognition: the LADIS study. J Neurol. 2006
Sep;253(9):1189-96.
132.
Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, FaxenIrving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to
moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch
Neurol. 2006 Oct;63(10):1402-8.
133.
Federspiel A, Volpe U, Horn H, Dierks T, Franck A, Vannini P, et al. Motion
standstill leads to activation of inferior parietal lobe. Hum Brain Mapp. 2006
Apr;27(4):340-9.
134.
de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al.
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive
impairment. Neurobiol Aging. 2006 Mar;27(3):394-401.
135.
Cavallin L, Danielsson R, Oksengard AR, Wahlund LO, Julin P, Frank A, et
al. Can dynamic susceptibility contrast magnetic resonance imaging replace singlephoton emission computed tomography in the diagnosis of patients with Alzheimer's
disease? A pilot study. Acta Radiol. 2006 Nov;47(9):977-85.
136.
Basile AM, Pantoni L, Pracucci G, Asplund K, Chabriat H, Erkinjuntti T, et
al. Age, hypertension, and lacunar stroke are the major determinants of the severity of
age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the
Elderly) Study. Cerebrovasc Dis. 2006;21(5-6):315-22.
137.
Annerbo S, Wahlund LO, Lokk J. The significance of thyroid-stimulating
hormone and homocysteine in the development of Alzheimer's disease in mild cognitive
impairment: a 6-year follow-up study. Am J Alzheimers Dis Other Demen. 2006 JunJul;21(3):182-8.
138.
van der Flier WM, van Straaten EC, Barkhof F, Ferro JM, Pantoni L, Basile
AM, et al. Medial temporal lobe atrophy and white matter hyperintensities are
associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. J
Neurol Neurosurg Psychiatry. 2005 Nov;76(11):1497-500.
139.
Wahlund LO, Almkvist O, Blennow K, Engedahl K, Johansson A, Waldemar
G, et al. Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool
in dementia workup. Top Magn Reson Imaging. 2005 Dec;16(6):427-37.
140.
Santana Santos F, Wahlund LO, Varli F, Tadeu Velasco I, Eriksdotter
Jonhagen M. Incidence, clinical features and subtypes of delirium in elderly patients
treated for hip fractures. Dement Geriatr Cogn Disord. 2005;20(4):231-7.
141.
Pettersson AF, Olsson E, Wahlund LO. Motor function in subjects with mild
cognitive impairment and early Alzheimer's disease. Dement Geriatr Cogn Disord.
2005;19(5-6):299-304.
142.
Pantoni L, Basile AM, Pracucci G, Asplund K, Bogousslavsky J, Chabriat H,
et al. Impact of age-related cerebral white matter changes on the transition to disability - the LADIS study: rationale, design and methodology. Neuroepidemiology. 2005;24(12):51-62.
143.
Ostberg P, Fernaeus SE, Hellstrom K, Bogdanovic N, Wahlund LO.
Impaired verb fluency: a sign of mild cognitive impairment. Brain Lang. 2005
Nov;95(2):273-9.
144.
Koenig T, Prichep L, Dierks T, Hubl D, Wahlund LO, John ER, et al.
Decreased EEG synchronization in Alzheimer's disease and mild cognitive impairment.
Neurobiol Aging. 2005 Feb;26(2):165-71.
145.
Johansson A, Zetterberg H, Hampel H, Buerger K, Prince JA, Minthon L, et
al. Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease.
Dement Geriatr Cogn Disord. 2005;20(6):367-74.
146.
Firbank MJ, O'Brien JT, Pakrasi S, Pantoni L, Simoni M, Erkinjuntti T, et al.
White matter hyperintensities and depression--preliminary results from the LADIS study.
Int J Geriatr Psychiatry. 2005 Jul;20(7):674-9.
147.
Annerbo S, Wahlund LO, Lokk J. The relation between homocysteine levels
and development of Alzheimer's disease in mild cognitive impairment patients. Dement
Geriatr Cogn Disord. 2005;20(4):209-14.
148.
Wolf H, Julin P, Gertz HJ, Winblad B, Wahlund LO. Intracranial volume in
mild cognitive impairment, Alzheimer's disease and vascular dementia: evidence for
brain reserve? Int J Geriatr Psychiatry. 2004 Oct;19(10):995-1007.
149.
Wolf H, Hensel A, Kruggel F, Riedel-Heller SG, Arendt T, Wahlund LO, et
al. Structural correlates of mild cognitive impairment. Neurobiol Aging. 2004
Aug;25(7):913-24.
150.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al.
Mild cognitive impairment--beyond controversies, towards a consensus: report of the
International Working Group on Mild Cognitive Impairment. J Intern Med. 2004
Sep;256(3):240-6.
151.
Vannini P, Almkvist O, Franck A, Jonsson T, Volpe U, Kristoffersen Wiberg
M, et al. Task demand modulations of visuospatial processing measured with functional
magnetic resonance imaging. Neuroimage. 2004 Jan;21(1):58-68.
152.
Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U,
et al. Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med.
2004 Feb;42(2):186-91.
153.
Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe
atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology.
2004 Jul 13;63(1):94-100.
154.
Frisoni GB, Padovani A, Wahlund LO. The predementia diagnosis of
Alzheimer disease. Alzheimer Dis Assoc Disord. 2004 Apr-Jun;18(2):51-3.
155.
Arnaiz E, Almkvist O, Ivnik RJ, Tangalos EG, Wahlund LO, Winblad B, et
al. Mild cognitive impairment: a cross-national comparison. J Neurol Neurosurg
Psychiatry. 2004 Sep;75(9):1275-80.
156.
Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for
prediction of Alzheimer's disease. Neurosci Lett. 2003 Nov 27;352(1):67-9.
157.
Wolf H, Kruggel F, Hensel A, Wahlund LO, Arendt T, Gertz HJ. The
relationship between head size and intracranial volume in elderly subjects. Brain Res.
2003 May 23;973(1):74-80.
158.
Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical
discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand
Suppl. 2003;179:52-76.
159.
Wahlund LO, Pihlstrand E, Jonhagen ME. Mild cognitive impairment:
experience from a memory clinic. Acta Neurol Scand Suppl. 2003;179:21-4.
160.
Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage
and intensity in cognitively impaired patients. Neurosci Lett. 2003 Mar 20;339(2):99-102.
161.
Nystrom H, Vannini P, Wahlund LO. [Functional MRI of the elderly can
complete the picture of cerebral functions]. Lakartidningen. 2003 Dec 18;100(5152):4278-82.
162.
Mulder C, Wahlund LO, Teerlink T, Blomberg M, Veerhuis R, van Kamp GJ,
et al. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid
in Alzheimer's disease. J Neural Transm. 2003 Aug;110(8):949-55.
163.
Lindau M, Jelic V, Johansson SE, Andersen C, Wahlund LO, Almkvist O.
Quantitative EEG abnormalities and cognitive dysfunctions in frontotemporal dementia
and Alzheimer's disease. Dement Geriatr Cogn Disord. 2003;15(2):106-14.
164.
Johansson A, Hampel H, Faltraco F, Buerger K, Minthon L, Bogdanovic N,
et al. Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2)
gene in patients with Alzheimer's disease and frontotemporal dementia. Neurosci Lett.
2003 Apr 3;340(1):69-73.
165.
Huang C, Wahlund LO, Almkvist O, Elehu D, Svensson L, Jonsson T, et al.
Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological
heterogeneity of mild cognitive impairment. Neuroimage. 2003 Jul;19(3):1137-44.
166.
Fukumoto H, Ingelsson M, Garevik N, Wahlund LO, Nukina N, Yaguchi Y,
et al. APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of
apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's
disease diagnosis. Exp Neurol. 2003 Sep;183(1):249-53.
167.
Frisoni GB, Scheltens P, Galluzzi S, Nobili FM, Fox NC, Robert PH, et al.
Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and
regional cerebral blood flow and metabolism: consensus paper of the EADC. J Neurol
Neurosurg Psychiatry. 2003 Oct;74(10):1371-81.
168.
Frisoni GB, Padovani A, Wahlund LO. The diagnosis of Alzheimer disease
before it is Alzheimer dementia. Arch Neurol. 2003 Jul;60(7):1023; author reply -4.
169.
Bronge L, Wahlund LO. Prognostic significance of white matter changes in
a memory clinic population. Psychiatry Res. 2003 Apr 1;122(3):199-206.
170.
Bohnstedt KC, Karlberg B, Wahlund LO, Jonhagen ME, Basun H, Schmidt
S. Determination of isoprostanes in urine samples from Alzheimer patients using porous
graphitic carbon liquid chromatography-tandem mass spectrometry. J Chromatogr B
Analyt Technol Biomed Life Sci. 2003 Oct 25;796(1):11-9.
171.
Almkvist O, Axelman K, Basun H, Jensen M, Viitanen M, Wahlund LO, et
al. Clinical findings in nondemented mutation carriers predisposed to Alzheimer's
disease: a model of mild cognitive impairment. Acta Neurol Scand Suppl. 2003;179:7782.
172.
Wahlund LO, Andersen C, Ostberg P. Standardizing frontotemporal
dementia: the problem of polysemy. Arch Neurol. 2002 Jul;59(7):1203-4; author reply 4.
173.
Tallberg IM, Persson H, Wangmar L, Wahlund LO, Almkvist O. Semantic
range and relevance of emotive utterances in patients with frontotemporal degeneration.
Brain Lang. 2002 Aug;82(2):146-58.
174.
Pettersson AF, Engardt M, Wahlund LO. Activity level and balance in
subjects with mild Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(4):213-6.
175.
Ostberg P, Andersen C, Wahlund LO. [Progressive aphasia. New data on
an old phenomenon]. Lakartidningen. 2002 Apr 25;99(17):1941-4.
176.
Mulder C, Wahlund LO, Blomberg M, de Jong S, van Kamp GJ, Scheltens
P, et al. Alzheimer's disease is not associated with altered concentrations of the nitric
oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid. J Neural
Transm. 2002 Sep;109(9):1203-8.
177.
Mulder C, Schoonenboom SN, Wahlund LO, Scheltens P, van Kamp GJ,
Veerhuis R, et al. CSF markers related to pathogenetic mechanisms in Alzheimer's
disease. J Neural Transm. 2002 Dec;109(12):1491-8.
178.
Jelic V, Konig T, Dierks T, Nordberg A, Wahlund LO.
Electroencephalography and glucose metabolism (positron-emission tomography) in
dementing disorders. Methods Find Exp Clin Pharmacol. 2002;24 Suppl D:21.
179.
Huang C, Wahlund LO, Svensson L, Winblad B, Julin P. Cingulate cortex
hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol.
2002 Sep 12;2:9.
180.
Fazekas F, Barkhof F, Wahlund LO, Pantoni L, Erkinjuntti T, Scheltens P,
et al. CT and MRI rating of white matter lesions. Cerebrovasc Dis. 2002;13 Suppl 2:316.
181.
Bronge L, Wahlund LO, Brauner A, Basun H, Garlind A. White matter
lesions and soluble interleukin-1 receptor type II in CSF from demented and nondemented subjects. Neurochem Int. 2002 Oct;41(4):217-22.
182.
Bronge L, Bogdanovic N, Wahlund LO. Postmortem MRI and
histopathology of white matter changes in Alzheimer brains. A quantitative, comparative
study. Dement Geriatr Cogn Disord. 2002;13(4):205-12.
183.
Almkvist O, Axelman K, Basun H, Wahlund LO, Lannfelt L. Conversion from
preclinical to dinical stage of Alzheimer's disease as shown by decline of cognitive
function in carriers of the Swedish APP-mutation. J Neural Transm Suppl.
2002(62):117-25.
184.
Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, et
al. A new rating scale for age-related white matter changes applicable to MRI and CT.
Stroke. 2001 Jun;32(6):1318-22.
185.
Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M,
Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93
years of age: establishment of reference values. Clin Chem. 2001 Oct;47(10):1776-81.
186.
Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, et al.
Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J
Neurosci Res. 2001 Nov 1;66(3):510-6.
187.
Radau PE, Slomka PJ, Julin P, Svensson L, Wahlund LO. Evaluation of
linear registration algorithms for brain SPECT and the errors due to hypoperfusion
lesions. Med Phys. 2001 Aug;28(8):1660-8.
188.
Ostberg P, Bogdanovic N, Fernaeus SE, Wahlund LO. Jargonagraphia in a
case of frontotemporal dementia. Brain Lang. 2001 Nov;79(2):333-9.
189.
Ingelson M, Fabre SF, Lilius L, Andersen C, Viitanen M, Almkvist O, et al.
Increased risk for frontotemporal dementia through interaction between tau
polymorphisms and apolipoprotein E epsilon4. Neuroreport. 2001 Apr 17;12(5):905-9.
190.
Forsell C, Enmark E, Axelman K, Blomberg M, Wahlund LO, Gustafsson
JA, et al. Investigations of a CA repeat in the oestrogen receptor beta gene in patients
with Alzheimer's disease. Eur J Hum Genet. 2001 Oct;9(10):802-4.
191.
Fernaeus SE, Almkvist O, Bronge L, Ostberg P, Hellstrom A, Winblad B, et
al. White matter lesions impair initiation of FAS flow. Dement Geriatr Cogn Disord. 2001
Jan-Feb;12(1):52-6.
192.
Fabre SF, Forsell C, Viitanen M, Sjogren M, Wallin A, Blennow K, et al.
Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau
and high apolipoprotein E epsilon4 frequency, but no tau gene mutations. Exp Neurol.
2001 Apr;168(2):413-8.
193.
Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Cerebrospinal
fluid tau levels increase with age in healthy individuals. Dement Geriatr Cogn Disord.
2001 Mar-Apr;12(2):127-32.
194.
Berg L, Gustafson L, Hansson G, Kilander L, Klingen S, Marcusson J, et al.
[Harmonization of dementia diagnoses--a necessary quality assurance]. Lakartidningen.
2001 Aug 22;98(34):3531-6.
195.
Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, et al.
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in
mild cognitive impairment. Neuroreport. 2001 Mar 26;12(4):851-5.
196.
Wahlund LO, Julin P, Johansson SE, Scheltens P. Visual rating and
volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a
comparative study. J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):630-5.
197.
Wahlund LO, Bronge L. Contrast-enhanced MRI of white matter lesions in
patients with blood-brain barrier dysfunction. Ann N Y Acad Sci. 2000 Apr;903:477-81.
198.
Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E.
Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the
cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 2000 Jan
14;278(3):169-72.
199.
Mattila KM, Axelman K, Rinne JO, Blomberg M, Lehtimaki T, Laippala P, et
al. Interaction between estrogen receptor 1 and the epsilon4 allele of apolipoprotein E
increases the risk of familial Alzheimer's disease in women. Neurosci Lett. 2000 Mar
17;282(1-2):45-8.
200.
Lindau M, Almkvist O, Kushi J, Boone K, Johansson SE, Wahlund LO, et al.
First symptoms--frontotemporal dementia versus Alzheimer's disease. Dement Geriatr
Cogn Disord. 2000 Sep-Oct;11(5):286-93.
201.
Jelic V, Johansson SE, Almkvist O, Shigeta M, Julin P, Nordberg A, et al.
Quantitative electroencephalography in mild cognitive impairment: longitudinal changes
and possible prediction of Alzheimer's disease. Neurobiol Aging. 2000 JulAug;21(4):533-40.
202.
Huang C, Wahlund L, Dierks T, Julin P, Winblad B, Jelic V. Discrimination
of Alzheimer's disease and mild cognitive impairment by equivalent EEG sources: a
cross-sectional and longitudinal study. Clin Neurophysiol. 2000 Nov;111(11):1961-7.
203.
Dierks T, Jelic V, Pascual-Marqui RD, Wahlund L, Julin P, Linden DE, et al.
Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of
intracerebral EEG-generators in Alzheimer's disease. Clin Neurophysiol. 2000
Oct;111(10):1817-24.
204.
Bronge L, Wahlund LO. White matter lesions in dementia: an MRI study on
blood-brain barrier dysfunction. Dement Geriatr Cogn Disord. 2000 Sep-Oct;11(5):2637.
205.
Bretillon L, Siden A, Wahlund LO, Lutjohann D, Minthon L, Crisby M, et al.
Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases.
Neurosci Lett. 2000 Oct 27;293(2):87-90.
206.
Andersen C, Jensen M, Lannfelt L, Lindau M, Wahlund LO. Amyloid
Abeta40 CSF concentrations correlate to frontal lobe atrophy in frontotemporal
dementia. Neuroreport. 2000 Feb 7;11(2):287-90.
207.
Andersen C, Froelich Fabre S, Ostberg P, Lannfelt L, Wahlund L. Tau
protein in cerebrospinal fluid from semantic dementia patients. Neurosci Lett. 2000 Nov
24;294(3):155-8.
208.
Wahlund LO, Julin P, Lindqvist J, Scheltens P. Visual assessment of
medical temporal lobe atrophy in demented and healthy control subjects: correlation
with volumetry. Psychiatry Res. 1999 Jun 30;90(3):193-9.
209.
Wahlund LO, Julin P, Lannfelt L, Lindqvist J, Svensson L. Inheritance of the
ApoE epsilon4 allele increases the rate of brain atrophy in dementia patients. Dement
Geriatr Cogn Disord. 1999 Jul-Aug;10(4):262-8.
210.
Wahlund LO, Basun H, Almkvist O, Julin P, Axelman K, Shigeta M, et al. A
follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease
mutation. Dement Geriatr Cogn Disord. 1999 Nov-Dec;10(6):526-33.
211.
Wahlund L, Bjorlin GA. Delirium in clinical practice: experiences from a
specialized delirium ward. Dement Geriatr Cogn Disord. 1999 Sep-Oct;10(5):389-92.
212.
Larsson M, Semb H, Winblad B, Amberla K, Wahlund LO, Backman L.
Odor identification in normal aging and early Alzheimer's disease: effects of retrieval
support. Neuropsychology. 1999 Jan;13(1):47-53.
213.
Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, et al.
Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and
declines with disease progression. Ann Neurol. 1999 Apr;45(4):504-11.
214.
Ingelson M, Blomberg M, Benedikz E, Wahlund LO, Karlsson E,
Vanmechelen E, et al. Tau immunoreactivity detected in human plasma, but no obvious
increase in dementia. Dement Geriatr Cogn Disord. 1999 Nov-Dec;10(6):442-5.
215.
Erkinjuntti T, Bowler JV, DeCarli CS, Fazekas F, Inzitari D, O'Brien JT, et
al. Imaging of static brain lesions in vascular dementia: implications for clinical trials.
Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S81-90.
216.
Bronge L, Fernaeus SE, Blomberg M, Ingelson M, Lannfelt L, Isberg B, et
al. White matter lesions in Alzheimer patients are influenced by apolipoprotein E
genotype. Dement Geriatr Cogn Disord. 1999 Mar-Apr;10(2):89-96.
217.
Scheltens P, Erkinjunti T, Leys D, Wahlund LO, Inzitari D, del Ser T, et al.
White matter changes on CT and MRI: an overview of visual rating scales. European
Task Force on Age-Related White Matter Changes. Eur Neurol. 1998;39(2):80-9.
218.
Robinson P, Ekman SL, Wahlund LO. Unsettled, uncertain and striving to
understand: toward an understanding of the situation of persons with suspected
dementia. Int J Aging Hum Dev. 1998;47(2):143-61.
219.
Lindau M, Almkvist O, Johansson SE, Wahlund LO. Cognitive and
behavioral differentiation of frontal lobe degeneration of the non-Alzheimer type and
Alzheimer's disease. Dement Geriatr Cogn Disord. 1998 Jul-Aug;9(4):205-13.
220.
Julin P, Almkvist O, Basun H, Lannfelt L, Svensson L, Winblad B, et al.
Brain volumes and regional cerebral blood flow in carriers of the Swedish Alzheimer
amyloid protein mutation. Alzheimer Dis Assoc Disord. 1998 Mar;12(1):49-53.
221.
Jelic V, Blomberg M, Dierks T, Basun H, Shigeta M, Julin P, et al. EEG
slowing and cerebrospinal fluid tau levels in patients with cognitive decline. Neuroreport.
1998 Jan 5;9(1):157-60.
222.
Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T,
Meyerson B, et al. Intracerebroventricular infusion of nerve growth factor in three
patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1998 Sep-Oct;9(5):24657.
223.
Almkvist O, Basun H, Backman L, Herlitz A, Lannfelt L, Small B, et al. Mild
cognitive impairment--an early stage of Alzheimer's disease? J Neural Transm Suppl.
1998;54:21-9.
224.
Yagyu T, Wackermann J, Shigeta M, Jelic V, Kinoshita T, Kochi K, et al.
Global dimensional complexity of multichannel EEG in mild Alzheimer's disease and
age-matched cohorts. Dement Geriatr Cogn Disord. 1997 Nov-Dec;8(6):343-7.
225.
Nordin S, Almkvist O, Berglund B, Wahlund LO. Olfactory dysfunction for
pyridine and dementia progression in Alzheimer disease. Arch Neurol. 1997
Aug;54(8):993-8.
226.
Lindh M, Blomberg M, Jensen M, Basun H, Lannfelt L, Engvall B, et al.
Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are
increased at follow up and show a correlation with levels of tau protein. Neurosci Lett.
1997 Jun 27;229(2):85-8.
227.
Julin P, Melin T, Andersen C, Isberg B, Svensson L, Wahlund LO.
Reliability of interactive three-dimensional brain volumetry using MP-RAGE magnetic
resonance imaging. Psychiatry Res. 1997 Nov 28;76(1):41-9.
228.
Julin P, Lindqvist J, Svensson L, Slomka P, Wahlund LO. MRI-guided
SPECT measurements of medial temporal lobe blood flow in Alzheimer's disease. J
Nucl Med. 1997 Jun;38(6):914-9.
229.
Jelic V, Julin P, Shigeta M, Nordberg A, Lannfelt L, Winblad B, et al.
Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's
disease as measured by EEG coherence. J Neurol Neurosurg Psychiatry. 1997
Jul;63(1):59-65.
230.
Dierks T, Jelic V, Julin P, Maurer K, Wahlund LO, Almkvist O, et al. EEGmicrostates in mild memory impairment and Alzheimer's disease: possible association
with disturbed information processing. J Neural Transm. 1997;104(4-5):483-95.
231.
Basun H, Almkvist O, Axelman K, Brun A, Campbell TA, Collinge J, et al.
Clinical characteristics of a chromosome 17-linked rapidly progressive familial
frontotemporal dementia. Arch Neurol. 1997 May;54(5):539-44.
232.
Andersen C, Dahl C, Almkvist O, Ostberg P, Julin P, Wahlund LO. Bilateral
temporal lobe volume reduction parallels cognitive impairment in progressive aphasia.
Arch Neurol. 1997 Oct;54(10):1294-9.
233.
Almkvist O, Basun H, Wagner SL, Rowe BA, Wahlund LO, Lannfelt L.
Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein
mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Arch
Neurol. 1997 May;54(5):641-4.
234.
Wahlund LO, Winblad B. Dementia: diagnostics, early treatment, and
assistance from family members. Acta Neurol Scand Suppl. 1996;168:2-21.
235.
Wahlund LO, Almkvist O, Basun H, Julin P. MRI in successful aging, a 5year follow-up study from the eighth to ninth decade of life. Magn Reson Imaging.
1996;14(6):601-8.
236.
Wahlund LO. Biological markers and diagnostic investigations in
Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:85-91.
237.
Wahlund LO. Magnetic resonance imaging and computed tomography in
Alzheimer's disease. Acta Neurol Scand Suppl. 1996;168:50-3.
238.
Jelic V, Shigeta M, Julin P, Almkvist O, Winblad B, Wahlund LO.
Quantitative electroencephalography power and coherence in Alzheimer's disease and
mild cognitive impairment. Dementia. 1996 Nov-Dec;7(6):314-23.
239.
Bronge LH, Wahlund LO, Isberg B. [Signal changes in the cerebral white
matter. Common findings by MRI examinations of the elderly]. Lakartidningen. 1996 Apr
17;93(16):1529-33.
240.
Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Increasing
cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E
allele epsilon 4 during 14 months follow-up. Neurosci Lett. 1996 Aug 23;214(2-3):163-6.
241.
Shigeta M, Julin P, Almkvist O, Basun H, Rudberg U, Wahlund LO. EEG in
successful aging; a 5 year follow-up study from the eighth to ninth decade of life.
Electroencephalogr Clin Neurophysiol. 1995 Aug;95(2):77-83.
242.
Lannfelt L, Basun H, Vigo-Pelfrey C, Wahlund LO, Winblad B, Lieberburg I,
et al. Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish
Alzheimer amyloid precursor protein mutation. Neurosci Lett. 1995 Oct 27;199(3):203-6.
243.
Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL. Decreased
alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for
Alzheimer's disease. Nat Med. 1995 Aug;1(8):829-32.
244.
Julin P, Wahlund LO, Basun H, Persson A, Mare K, Rudberg U. Clinical
diagnosis of frontal lobe dementia and Alzheimer's disease: relation to cerebral
perfusion, brain atrophy and electroencephalography. Dementia. 1995 MayJun;6(3):142-7.
245.
Wahlund LO, Basun H, Almkvist O, Andersson-Lundman G, Julin P, Saaf J.
White matter hyperintensities in dementia: does it matter? Magn Reson Imaging.
1994;12(3):387-94.
246.
Wahlund LO. Brain imaging and vascular dementia. Dementia. 1994 MayAug;5(3-4):193-6.
247.
Wahlund LO, Andersson-Lundman G, Basun H, Almkvist O, Bjorksten KS,
Saaf J, et al. Cognitive functions and brain structures: a quantitative study of CSF
volumes on Alzheimer patients and healthy control subjects. Magn Reson Imaging.
1993;11(2):169-74.
248.
Sohlstrom A, Wahlund LO, Forsum E. Total body fat and its distribution
during human reproduction as assessed by magnetic resonance imaging. Basic Life
Sci. 1993;60:181-4.
249.
Sohlstrom A, Wahlund LO, Forsum E. Adipose tissue distribution as
assessed by magnetic resonance imaging and total body fat by magnetic resonance
imaging, underwater weighing, and body-water dilution in healthy women. Am J Clin
Nutr. 1993 Dec;58(6):830-8.
250.
Almkvist O, Backman L, Basun H, Wahlund LO. Patterns of
neuropsychological performance in Alzheimer's disease and vascular dementia. Cortex.
1993 Dec;29(4):661-73.
251.
Wahlund LO, Andersson-Lundman G, Julin P, Nordstrom M, Viitanen M,
Saaf J. Quantitative estimation of brain white matter abnormalities in elderly subjects
using magnetic resonance imaging. Magn Reson Imaging. 1992;10(6):859-65.
252.
Wahlund LO, Agartz I, Saaf J, Wetterberg L, Marions O. MRI in psychiatry:
731 cases. Psychiatry Res. 1992 Aug;45(2):139-40.
253.
Almkvist O, Wahlund LO, Andersson-Lundman G, Basun H, Backman L.
White-matter hyperintensity and neuropsychological functions in dementia and healthy
aging. Arch Neurol. 1992 Jun;49(6):626-32.
254.
Agartz I, Saaf J, Wahlund LO, Wetterberg L. Quantitative estimations of
cerebrospinal fluid spaces and brain regions in healthy controls using computerassisted tissue classification of magnetic resonance images: relation to age and sex.
Magn Reson Imaging. 1992;10(2):217-26.
255.
Agartz I, Marions O, Saaf J, Wahlund LO, Wetterberg L. Visual rating of
magnetic resonance images of human cerebrospinal fluid spaces and white brain
matter: relation to sex and age in healthy volunteers. Magn Reson Imaging.
1992;10(1):135-42.
256.
Ekman G, de Chateau P, Marions O, Sellden H, Wahlund LO, Wetterberg
L. Low field magnetic resonance imaging of the central nervous system in 15 children
with autistic disorder. Acta Paediatr Scand. 1991 Feb;80(2):243-7.
257.
Agartz I, Saaf J, Wahlund LO, Wetterberg L. T1 and T2 relaxation time
estimates in the normal human brain. Radiology. 1991 Nov;181(2):537-43.
258.
Agartz I, Saaf J, Wahlund LO, Wetterberg L. T1 and T2 relaxation time
estimates and brain measures during withdrawal in alcoholic men. Drug Alcohol
Depend. 1991 Dec 31;29(2):157-69.
259.
Wahlund LO, Agartz I, Almqvist O, Basun H, Forssell L, Saaf J, et al. The
brain in healthy aged individuals: MR imaging. Radiology. 1990 Mar;174(3 Pt 1):675-9.
260.
Sonnerborg A, Saaf J, Alexius B, Strannegard O, Wahlund LO, Wetterberg
L. Quantitative detection of brain aberrations in human immunodeficiency virus type 1infected individuals by magnetic resonance imaging. J Infect Dis. 1990
Dec;162(6):1245-51.
261.
Sellden H, de Chateau P, Ekman G, Linder B, Saaf J, Wahlund LO.
Circulatory monitoring of children during anaesthesia in low-field magnetic resonance
imaging. Acta Anaesthesiol Scand. 1990 Jan;34(1):41-3.
262.
Samuelsson L, Saaf J, Wahlund LO, Thuomas KA, Bergstrom K. Evaluation
of syringomyelia and Chiari malformations using ultra-low magnetic resonance imaging.
Magn Reson Imaging. 1990;8(2):123-9.
263.
Linne T, Agartz I, Saaf J, Wahlund LO. Cerebral abnormalities in Wilson's
disease as evaluated by ultra-low-field magnetic resonance imaging and computerized
image processing. Magn Reson Imaging. 1990;8(6):819-24.
264.
Wahlund LO, Saaf J, Freund Y, Marions O, Rudberg U. Reduced blood flow
in the transverse sinus visualized by ultra low field magnetic resonance imaging. Magn
Reson Imaging. 1989 Jan-Feb;7(1):101-4.
265.
Wahlund LO, Boethius J, Kindstrand E, Marions O, Saaf J, Wetterberg L. A
new method for characterization of low grade gliomas using ultra low field magnetic
resonance imaging. Magn Reson Imaging. 1989 Nov-Dec;7(6):599-603.
266.
Wahlund LO, Agartz I, Saaf J, Wetterberg L, Marions O. [Magnetic
resonance tomography in psychiatry--clear benefits for health care services].
Lakartidningen. 1989 Nov 15;86(46):3991-4.
267.
Freund-Levi Y, Saaf J, Wahlund LO, Wetterberg L. Ultra low field brain MRI
in HIV transfusion infected patients. Magn Reson Imaging. 1989 Mar-Apr;7(2):225-30.
268.
Neiman J, Borg S, Wahlund LO. Parkinsonism and dyskinesias during
ethanol withdrawal. Br J Addict. 1988 Apr;83(4):437-9.
269.
Agartz I, Saaf J, Wahlund LO, Wetterberg L. Magnetic resonance imaging
at 0.02 T in clinical practice and research. Magn Reson Imaging. 1987;5(3):179-87.
270.
Wahlund LO, Saaf J, Eneroth-Grimfors E, Nilsson BA, Bevegard S.
Reduced platelet MAO activity during pregnancy. Acta Physiol Scand. 1986
Jan;126(1):135-8.
271.
Agartz I, Saaf J, Wahlund B, Wahlund LO, Wetterberg L. High accuracy
and contrast resolution in ultra-low field magnetic resonance imaging. Acta Radiol
Suppl. 1986;369:472-4.
272.
Agartz I, Saaf J, Wahlund LO, Wetterberg L, Ahlback SO, Rydberg J. [Good
experiences with a newly installed nuclear magnetic resonance camera].
Lakartidningen. 1985 Nov 20;82(47):4116-21.
273.
Waldenlind E, Saaf J, Ekbom K, Ross S, Wahlund LO, Wetterberg L.
Kinetics and thermolability of platelet monoamine oxidase in cluster headache and
migraine. Cephalalgia. 1984 Jun;4(2):125-34.
274.
Wahlund LO, Saaf J, Ross SB, Wetterberg L, Smedby Y. Kinetic aspects of
human platelet monoamine oxidase thermolability. Acta Physiol Scand. 1984
Oct;122(2):97-102.
275.
Wahlund LO, Saaf J, Ross SB, Wetterberg L. Activation of monoamine
oxidase by high molecular weight fractions of human plasma. Acta Physiol Scand. 1984
Mar;120(3):337-41.
276.
Salum I, Wahlund LO. [Fatal methanol poisoning--a warning against nonspecific alcohol tests]. Lakartidningen. 1984 Aug 8;81(32-33):2820.
277.
Wahlund LO, Smedby Y, Saaf J, Schulman A, Ross AB, Wetterberg L.
Influence of hemodialysis on monoamine oxidase kinetics in platelets from chronic
schizophrenic patients. Artif Organs. 1983 Aug;7(3):334-9.
278.
Schulman A, Salum I, Wahlund LO, Wetterberg L, Asaba H, Bergstrom J, et
al. Hemodialysis in the treatment of chronic schizophrenic patients: a double-blind
crossover study. Artif Organs. 1983 Aug;7(3):326-33.
279.
Koide Y, Saaf J, Wahlund LO, Roos SB, Wetterberg L. Platelet monoamine
oxidase activity in schizophrenic families - kinetic aspects. Clin Genet. 1981
May;19(5):405-9.
280.
Koide Y, Saaf J, Roos SB, Wahlund LO, Wetterberg L. Activity of platelet
monoamine oxidase in apparently health subjects. Clin Genet. 1981 May;19(5):400-5.
281.
Koide Y, Eberhard G, Saaf J, Ross SB, Wahlund LO, Wetterberg L. Kinetic
aspects of monoamine oxidase activity in twins with psychoses. Clin Genet. 1981
May;19(5):395-400.